Erratum: Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease (Dementia and Geriatric Cognitive Disorders (2012) 33 (416-422) DOI:10.1159/000339367);Impact of beta-amyloid-specific florbetaben pet imaging on confidence in early diagnosis of Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 33, Issue 6, 2012, Pages 416-422

  Schipke, C G ^b   Peters, O ^b   Heuser, I ^b   Grimmer, T ^d   Sabbagh, M N ^a   Sabri, O ^e   Hock, C ^f   Kunz, M ^c   Kuhlmann, J ^c   Reininger, C ^c   Blankenburg, M ^c  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BAYER PHARMA AG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Alzheimer's disease; Beta amyloid plaques; Florbetaben amyloid imaging

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE DURATION; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 84863880089     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000339367     Document Type: Erratum

References (20)

1. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hull M, Frolich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schroder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J: Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012;78:379-386.
2. Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L: Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord 2010;29:204-212.
3. Blennow K, Vanmechelen E: Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm Suppl 1998;53: 223-235. (Pubitemid 28361783)
4. Teipel SJ, Peters O, Heuser I, Jessen F, Maier W, Froelich L, Arlt S, Hull M, Gertz HJ, Kornhuber J, Wiltfang J, Thome J, Rienhoff O, Meindl T, Hampel H, Grothe M: Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: effect of different processing and analysis approaches on sample sizes. World J Biol Psychiatry 2011;12(suppl 1): 109-113.
5. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J: Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 2004;23: 115-122. (Pubitemid 41359194)
6. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010;15:138-145.
7. Schipke CG, Jessen F, Teipel S, Luckhaus C, Wiltfang J, Esselmann H, Frolich L, Maier W, Ruther E, Heppner FL, Prokop S, Heuser I, Peters O: Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. J Alzheimers Dis 2011;26: 255-262.
8. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257-262.
9. Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
10. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9: 119-128.
11. Schipke CG, Prokop S, Heppner FL, Heuser I, Peters O: Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. Dement Geriatr Cogn Disord 2011; 31:139-145.
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65: 403-413.
13. Mattsson N, Andreasson U, Persson S, Arai H, et al: The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7:386-395.e386.
14. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA: Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005;51:189-195. (Pubitemid 40024030)
15. Wang Y, Klunk WE, Debnath ML, Huang GF, Holt DP, Shao L, Mathis CA: Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci 2004;24:55-62. (Pubitemid 41359167)
16. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O: Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424-435.
17. Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O: Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging DOI: 10.1007/ s00259-011-1821-1.
18. Kornhuber J, Schmidtke K, Frolich L, Perneczky R, Wolf S, Hampel H, Jessen F, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hull M, Gertz HJ, Schroder J, Pantel J, Rienhoff O, Seuchter SA, Ruther E, Henn F, Maier W, Wiltfang J: Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German DementiaCompetenceNetwork. Dement Geriatr Cogn Disord 2009;27:404-417.
19. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, Tapiola T, Pirttila T, Rinne J, Jaaskelainen JE, Soininen H, Rinne JO: Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 2008;65:1304-1309.
20. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST: Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131: 1630-1645. (Pubitemid 351806448)